Tag:

Eli Lilly

Latest Headlines

Latest Headlines

FDA's OK for Boehringer Ingelheim plant gives it and Lilly hope on diabetes drug

Boehringer Ingelheim's manufacturing facility in Ingelheim, Germany has generated a lot of mail from the FDA. Finally, some good news: The company said today it received a letter from the FDA clearing the plant, meaning it and partner Eli Lilly can move forward with empagliflozin.

Eli Lilly gets on the trial transparency bandwagon

In keeping with changing industry standards, Eli Lilly has joined the host of drugmakers opening up their data vaults, going further than some but not quite baring it all.

Lilly's ramucirumab scores a marginal gain for lung cancer patients

Eli Lilly wrestled its way into the spotlight at ASCO Saturday morning with evidence that its cancer drug ramucirumab delivers a marginal benefit for patients suffering from advanced non-small cell lung cancer. And analysts quickly heralded the data, saying it should help pave the way to quickly broaden the market for this drug.

Qiagen and Lilly continue successful string of diagnostics partnerships

Qiagen and Eli Lilly have joined forces for their fourth companion diagnostics project, building on the momentum of past collaborations to develop assay panels for cancer.

Qiagen and Lilly pair in their 4th cancer companion Dx project

Qiagen and Eli Lilly have clicked well enough in previous companion diagnostics development projects that they're signing up for a fourth go-around.

Investigator database looking for new members after adding Novartis and Pfizer to ranks

Having made the big decisions about how their database of clinical trial investigators will work, collaborators Eli Lilly, Merck and Johnson & Johnson are looking to add more members to a roster already swelled by the arrival of Novartis and Pfizer.

Bayer strikes deal with arGEN-X, Lilly backs U.K. VC fund, Czech biotech in immunotherapy first

In this week's EuroBiotech Report, Bayer became the most recent biopharma to tap Dutch biotech arGEN-X for its llama-based antibody discovery platform; Eli Lilly made its first-ever investment in a British venture fund; and British biotech Oxford BioMedica hopes to raise £25.7 million to finance its gene therapy pipeline. And more.

Lilly steps out of its comfort zone, backs an international biotech fund

Eli Lilly has taken the unusual step of investing in Epidarex Capital's new, $80 million life sciences fund, with an eye to backing the Scotland-based group's portfolio of academic spinouts. This was Lilly's first investment in a U.K. venture fund.

Actavis commits $48M to revitalizing Puerto Rico plants

Puerto Rico's drug production sector has had an eventful few years, with investments by Eli Lilly, Bristol-Myers Squibb and others being offset by cutbacks at Merck and Pfizer. Now the island can add another line to its list of positive events: Actavis is investing $48 million to revitalize assets it acquired in the takeover of Warner Chilcott.

Got a problem, doc? In Eli Lilly's brave new sales world, that's a plus

New sales models are trendy in Big Pharma. Actually, they're de rigueur: With thousands fewer drug reps on the street these days, and many doctors turning reps away, companies have had to turn to new ways of promoting their products. Plus, all those pesky Department of Justice settlements make the old hard sell seem sketchy.